D Tc 99m Dimercaptosuccinic Acid SPECT Versus Planar
Sponsor
Assiut University (Other)
Overall Status
Unknown status
CT.gov ID
NCT04091685
Collaborator
(none)
50
13
Study Details
Study Description
Brief Summary
Knowing what will DMSA spect add to the DMSA planar in detection in renal cortical defects
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
50 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Added Value of Tc99m Dimercaptosuccinic Acid SPECT Versus Planar Imaging in Detection of Renal Cortical Defects
Anticipated Study Start Date
:
Sep 1, 2019
Anticipated Primary Completion Date
:
Sep 1, 2020
Anticipated Study Completion Date
:
Oct 1, 2020
Outcome Measures
Primary Outcome Measures
- Comparison between DMSA spect and planar imaging [Baseline]
Analysis of DMSA spect and planar imaging to clarify early renal cortical defects
Secondary Outcome Measures
- Clarify added value of DMSA spect over planar [Baseline]
Know if DMSA spect is necessary?
Eligibility Criteria
Criteria
Ages Eligible for Study:
N/A
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
- patient with history of peylo nephritis.
Exclusion Criteria:
- pregnant women
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Assiut University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Marwa Sayed Mohamed,
Resident doctor,
Assiut University
ClinicalTrials.gov Identifier:
NCT04091685
Other Study ID Numbers:
- DSVP
First Posted:
Sep 17, 2019
Last Update Posted:
Sep 17, 2019
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No